BioSpace News Archive

Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases announced today that it will have four poster presentations at ID Week 2022.

10x Genomics announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 2, 2022.

23andMe Holding Co. announced that management will be participating in investor presentations at the following conferences:

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

QuidelOrtho Corporation (NASDAQ: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the third quarter ended October 2, 2022.

Labcorp, a leading global life sciences company, announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, announced that its collaboration with CPI is demonstrating the value of at-line cell culture media analysis to inform feeding strategies for improved cell growth in bioprocessing applications.

BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2022, to shareholders of record at the close of business on November 30, 2022.

DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced the pricing of its upsized underwritten public offering of 8,219,178 shares of its common stock at a public offering price of $36.50 per share.

Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, announced it will present an analysis of a Phase 3 safety study of VALTOCO® CIV at the 2022 Annual Meeting of the Academy of Managed Care Pharmacy, Oct. 14 to 22, in National Harbor, MD.